Breaking News, Financial News

Catalent Revenues up 4% in the Quarter

Biologics revenue up 3% and Pharma and Consumer Health revenue up 5%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Catalent 1Q Revenues: $1.02 billion (+4%) 1Q Loss: $129 million (loss of $759 million Fiscal 1Q24) Comments: Biologics revenue was $461 million in the quarter, up 3%. Pharma and Consumer Health revenues were $563, up 5%. After excluding COVID-related revenue of approximately $30 million in the first quarter of fiscal 2025 and approximately $100 million in first quarter of fiscal 2024, net revenue increased 13%.   The merger agreement under which Novo Holdings will acquire Catalent in an all...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters